Atom Investors LP Invests $4.09 Million in DaVita Inc. (NYSE:DVA)

Atom Investors LP purchased a new stake in shares of DaVita Inc. (NYSE:DVA - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 24,977 shares of the company's stock, valued at approximately $4,094,000.

Several other large investors have also recently added to or reduced their stakes in the company. Transcendent Capital Group LLC bought a new position in shares of DaVita during the third quarter valued at approximately $25,000. Blue Trust Inc. grew its stake in DaVita by 58.6% during the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company's stock worth $29,000 after buying an additional 78 shares during the last quarter. Family Firm Inc. acquired a new stake in DaVita in the second quarter worth $43,000. Versant Capital Management Inc lifted its stake in DaVita by 90.6% in the second quarter. Versant Capital Management Inc now owns 326 shares of the company's stock valued at $45,000 after buying an additional 155 shares during the last quarter. Finally, Friedenthal Financial acquired a new position in shares of DaVita during the second quarter valued at $48,000. 90.12% of the stock is currently owned by institutional investors.

DaVita Price Performance

DVA traded down $2.43 during trading on Monday, reaching $163.74. The stock had a trading volume of 692,762 shares, compared to its average volume of 820,514. DaVita Inc. has a 1-year low of $103.40 and a 1-year high of $169.51. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78. The stock has a 50 day moving average of $158.57 and a two-hundred day moving average of $149.48. The firm has a market capitalization of $13.43 billion, a price-to-earnings ratio of 17.93, a price-to-earnings-growth ratio of 0.94 and a beta of 0.89.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing analysts' consensus estimates of $2.76 by ($0.17). DaVita had a net margin of 6.53% and a return on equity of 88.18%. The business had revenue of $3.26 billion during the quarter, compared to analyst estimates of $3.25 billion. During the same period in the previous year, the company posted $2.85 earnings per share. DaVita's revenue was up 4.6% compared to the same quarter last year. As a group, equities analysts anticipate that DaVita Inc. will post 9.71 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Barclays lifted their price objective on shares of DaVita from $150.00 to $164.00 and gave the company an "equal weight" rating in a research report on Thursday, October 31st. Truist Financial lifted their price target on DaVita from $165.00 to $175.00 and gave the company a "hold" rating in a report on Monday, October 7th. Bank of America increased their price objective on DaVita from $139.00 to $145.00 and gave the stock an "underperform" rating in a report on Wednesday, August 7th. Finally, UBS Group lifted their target price on DaVita from $169.00 to $175.00 and gave the company a "buy" rating in a research note on Thursday, August 8th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $161.80.

Insider Buying and Selling at DaVita

In other DaVita news, CEO Javier Rodriguez sold 50,000 shares of the firm's stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $165.05, for a total value of $8,252,500.00. Following the completion of the transaction, the chief executive officer now directly owns 837,835 shares in the company, valued at $138,284,666.75. This trade represents a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 2.00% of the stock is owned by corporate insiders.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.